Navigation Links
Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
Date:3/24/2009

REVIEW OF RESULTS CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGE

NANTONG CITY, China, March 24 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) is pleased to announce that its patented version of Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as Kutai in China, has successfully concluded its Phase IV Clinical Study.

The multi-center Phase IV Clinical Study investigated the safety and effectiveness of Kutai's use at room temperature. The after-market study, supported by the National Multi-center Clinical plan, was concluded successfully on September 2, 2008.

Kutai is a non-depolarizing skeletal muscle relaxant for intravenous administration. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action.

More than 30 clinical experts from seven participating medical centers within China gathered in Nanjing for a conference to review the results of the Phase IV of the Kutai Multi-center clinical study project.

Ms. Xinming Wu, Chief anesthetist of No.1 Hospital of Chinese Peking University Anesthesia Department, presided over the conference and delivered a summary report of the Phase IV project. Xuejun Chen, Sinobiopharma's vice president of sales was also in attendance and expressed Sinobiopharma's thanks to the participating experts for their commitment to research on Kutai.

Sinobiopharma has established a highly specialized professional team of clinical trial monitors as part of the project to keep close surveillance on the patients. The manager of Sinobiopharma's Clinical Research Department, Mr. Lei Wang, reported on the Phase IV project clinical monitoring outcomes.

The experts' consensus was that the Phase IV study established Kutai as safe and effective for room temperature storage. The year-long clinical research project showed no significant differences between Kutai and imported Cisatracurium besylate, and no significant differences for Kutai safety and effectiveness when stored at either room temperature or a lower temperature.

All the participating parties followed the study design and promote inter-communication to ensure compliance with Good Clinical Practice (GCP).

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
2. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
3. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
4. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
5. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
6. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
9. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis today filled prescriptions ... Minnich,s Pharmacy in York to ... by Dr. Levine as a prescription to acquire naloxone ... "It,s important to remember that any Pennsylvanian can walk ...
(Date:12/5/2016)... Research and Markets has announced the ... Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & ... report to their offering. ... , , The western ... from USD 574.8 Million in 2016, growing at a CAGR of ...
(Date:12/5/2016)... CALEDONIA, Mich. , Dec. 5, 2016  Sharn ... a preferred anesthesia sales and distribution partner for Salter ... Dealer of the Year in recognition of outstanding sales ... of devices for respiratory and anesthesia care, including the ... company is also the master distributor of the Parker ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins ... growing brains of young athletes. Over the course of three years, researchers will study ... mouth guards. The mouth guards, equipped with special sensors, will track the location and ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... Isles Beach, Fla (PRWEB) , ... December 05, ... ... E. Herman as Keynote speaker for the 21st Annual International Congress on Hematologic ... making the announcement, PER® president, Phil Talamo said, “We are honored to have ...
(Date:12/5/2016)... Missouri (PRWEB) , ... December 05, 2016 , ... ... ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has always ... treatment accessible to as many people as possible. In that spirit, Castlewood ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
Breaking Medicine News(10 mins):